| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||||||||
| Ordinary shares, nominal value £0.001 per share | * | The Nasdaq Stock Market LLC* | ||||||||||||
| Large Accelerated filer | o | Accelerated filer | o | x | Emerging Growth Company | ||||||||||||||||||
| x | International Financial Reporting Standards as issued by the International Accounting Standards Board | o | Other | o | |||||||||||||
| Page | ||||||||
| PART I | ||||||||
| Item 1. | ||||||||
| Item 2. | ||||||||
| Item 3. | ||||||||
| Item 4. | ||||||||
| Item 4A. | ||||||||
| Item 5. | ||||||||
| Item 6. | ||||||||
| Item 7. | ||||||||
| Item 8. | ||||||||
| Item 9. | ||||||||
Item 10. | ||||||||
| Item 11. | ||||||||
| Item 12. | ||||||||
| Part II | ||||||||
| Item 13. | ||||||||
| Item 14. | ||||||||
| Item 15. | ||||||||
| Item 16. | ||||||||
| Item 16A. | ||||||||
| Item 16B. | ||||||||
| Item 16C. | ||||||||
| Item 16D. | ||||||||
| Item 16E. | ||||||||
| Item 16F. | ||||||||
| Item 16G. | ||||||||
| Item 16H. | ||||||||
| Item 16I. | ||||||||
| Item 16J. | ||||||||
| Item 16K. | ||||||||
| Part III | ||||||||
| Item 17. | ||||||||
| Fiscal Year Ended March 31, | |||||||||||||||||||||||||||||
| (in millions, except percentages) | 2024 | % of revenue | 2023 | % of revenue | 2022 | % of revenue | |||||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||||||||
| Revenue from external customers | $ | 2,509 | 78 | % | $ | 2,025 | 76 | % | $ | 2,219 | 82 | % | |||||||||||||||||
| Revenue from related parties | 724 | 22 | % | 654 | 24 | % | 484 | 18 | % | ||||||||||||||||||||
| Total revenue | 3,233 | 100 | % | 2,679 | 100 | % | 2,703 | 100 | % | ||||||||||||||||||||
| Cost of sales | (154) | 5 | % | (106) | 4 | % | (131) | 5 | % | ||||||||||||||||||||
| Gross profit | 3,079 | 95 | % | 2,573 | 96 | % | 2,572 | 95 | % | ||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||||||||
| Research and development | (1,979) | 61 | % | (1,133) | 42 | % | (995) | 37 | % | ||||||||||||||||||||
| Selling, general and administrative | (983) | 30 | % | (762) | 28 | % | (897) | 33 | % | ||||||||||||||||||||
| Impairment of long-lived assets | — | 0 | % | — | 0 | % | (21) | 1 | % | ||||||||||||||||||||
| Disposal, restructuring and other operating expenses, net | (6) | 0 | % | (7) | 0 | % | (26) | 1 | % | ||||||||||||||||||||
| Total operating expense | (2,968) | 92 | % | (1,902) | 71 | % | (1,939) | 72 | % | ||||||||||||||||||||
| Operating income (loss) | 111 | 3 | % | 671 | 25 | % | 633 | 23 | % | ||||||||||||||||||||
| Income (loss) from equity investments, net | (20) | 1 | % | (45) | 2 | % | 141 | 5 | % | ||||||||||||||||||||
| Interest income, net | 110 | 3 | % | 42 | 2 | % | 2 | 0 | % | ||||||||||||||||||||
| Other non-operating income (loss), net | 11 | — | % | 3 | — | % | 10 | 0 | % | ||||||||||||||||||||
| Income (loss) before income taxes | 212 | 7 | % | 671 | 25 | % | 786 | 29 | % | ||||||||||||||||||||
| Income tax benefit (expense) | 94 | 3 | % | (147) | 5 | % | (110) | 4 | % | ||||||||||||||||||||
| Net income (loss) | $ | 306 | 9 | % | $ | 524 | 20 | % | $ | 676 | 25 | % | |||||||||||||||||
| Fiscal Year Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||
| External Customers | Related Parties | Total | |||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | 2024 | 2023 | % Change | 2024 | 2023 | % Change | ||||||||||||||||||||||||||||||||||||||
| License and Other Revenue | $ | 1,051 | $ | 569 | 85 | % | $ | 380 | $ | 435 | (13) | % | $ | 1,431 | $ | 1,004 | 43 | % | |||||||||||||||||||||||||||||
| Royalty Revenue | 1,458 | 1,456 | — | % | 344 | 219 | 57 | % | 1,802 | 1,675 | 8 | % | |||||||||||||||||||||||||||||||||||
| $ | 2,509 | $ | 2,025 | 24 | % | $ | 724 | $ | 654 | 11 | % | $ | 3,233 | $ | 2,679 | 21 | % | ||||||||||||||||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Cost of sales | $ | (154) | $ | (106) | 45% | |||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Research and development | $ | (1,979) | $ | (1,133) | 75% | |||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Selling, general and administrative | $ | (983) | $ | (762) | 29 | % | ||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Disposal, restructuring and other operating expenses, net | $ | (6) | $ | (7) | (14) | % | ||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Income (loss) from equity investments, net | $ | (20) | $ | (45) | (56) | % | ||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Interest income, net | $ | 110 | $ | 42 | 162 | % | ||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Other non-operating income (loss), net | $ | 11 | $ | 3 | 267 | % | ||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions, except percentages) | 2024 | 2023 | % Change | |||||||||||||||||
| Income tax benefit (expense) | $ | 94 | $ | (147) | (164) | % | ||||||||||||||
| Income (loss) before income taxes | $ | 212 | $ | 671 | (68) | % | ||||||||||||||
| Income tax benefit (expense) as a percentage of income before taxes | 44.3 | % | (21.9) | % | ||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Net cash provided by (used for) operating activities | $ | 1,090 | $ | 739 | $ | 458 | ||||||||||||||
| Net cash provided by (used for) investing activities | $ | (516) | $ | (138) | $ | (619) | ||||||||||||||
| Net cash provided by (used for) financing activities | $ | (208) | $ | (42) | $ | (32) | ||||||||||||||
| Effect of foreign exchange rate changes on cash and cash equivalents | $ | 3 | $ | (9) | $ | (17) | ||||||||||||||
| Net increase (decrease) in cash and cash equivalents | $ | 369 | $ | 550 | $ | (210) | ||||||||||||||
| Cash and cash equivalents at the beginning of the period | $ | 1,554 | $ | 1,004 | $ | 1,214 | ||||||||||||||
| Cash and cash equivalents at the end of the period | $ | 1,923 | $ | 1,554 | $ | 1,004 | ||||||||||||||
| Name | Age | Position(s) | ||||||||||||
| Non-Executive Directors: | ||||||||||||||
| Masayoshi Son | 66 | Chairman of the Board of Directors | ||||||||||||
| Ronald D. Fisher | 76 | Director | ||||||||||||
| Jeffrey A. Sine | 69 | Director | ||||||||||||
| Karen E. Dykstra | 65 | Director | ||||||||||||
| Anthony Michael Fadell | 55 | Director | ||||||||||||
| Rosemary Schooler | 56 | Director | ||||||||||||
| Paul E. Jacobs, PhD | 61 | Director | ||||||||||||
| Senior Management: | ||||||||||||||
| Rene Haas | 61 | Chief Executive Officer and Director | ||||||||||||
| Jason Child | 55 | Executive Vice President and Chief Financial Officer | ||||||||||||
| Kirsty Gill | 51 | Executive Vice President and Chief People Officer | ||||||||||||
| Spencer Collins | 43 | Executive Vice President and Chief Legal Officer | ||||||||||||
| Richard Grisenthwaite | 56 | Executive Vice President and Chief Architect | ||||||||||||
| Will Abbey | 53 | Executive Vice President and Chief Commercial Officer | ||||||||||||
Board Diversity Matrix (as of the date of this Annual Report) | |||||
| Country of Principal Executive Offices | United Kingdom | ||||
| Foreign Private Issuer | Yes | ||||
| Disclosure Prohibited Under Home Country Law | No | ||||
| Total Number of Directors | 8 | ||||
| Female | Male | Non-Binary | Did Not Disclose Gender | |||||||||||
| Part I: Gender Identity | ||||||||||||||
| Directors | 2 | 3 | 0 | 3 | ||||||||||
| Part II: Demographic Background | |||||
| LGBTQ+ | 0 | ||||
| Underrepresented in Home Country Jurisdiction | 0 | ||||
| Did Not Disclose Demographic Background | 3 | ||||
| Base Salary | |||||
| Purpose and link to strategy | To provide fixed remuneration to the Executive Director to reflect the responsibilities of the role. To attract and retain the highest caliber talent from the global technology industry, including within the context of our growth aspirations. | ||||
| Operation | The Executive Director's salary is reviewed annually by the Remuneration Committee and any increase or adjustment is usually applied from April 1st of each year. When reviewing the Executive Director's salary, the Remuneration Committee will take into account the general market movements, salary levels for comparable roles in comparable companies, the performance of the Company and the individual and any changes to the scope and/or responsibility of the role. | ||||
| Maximum | There is no defined maximum salary. The salary and any increases are determined by the Remuneration Committee based on the factors described above. | ||||
| Performance conditions | N/A | ||||
| Benefits | |||||
| Purpose and link to strategy | To provide competitive benefits that enable our people’s wellbeing. Benefits align with the wider workforce and reflect those commonly available in the Executive Director’s home country. | ||||
| Operation | Benefits provided to the Executive Director include vacation, health coverage and insurance, accident and disability insurance, and group life insurance. The Executive Director is also eligible to receive benefits offered to the wider workforce within their home country. Situation-specific taxable benefits may be provided as may be required in the interests of the Company’s business such as, but not limited to, company paid car or telephone, car allowance, memberships, directors and officers indemnification and insurance cover, and tax return preparation and advice. Executive Directors may receive other benefits that are judged to be cost-effective and appropriate in terms of the individual’s role, time and/or security. Where applicable, we may provide housing or relocation allowances, travel allowance and expenses, tax equalization or other expatriate benefits, and where necessary some or all of these benefits may be grossed up for taxes. Other benefits may be provided if the Remuneration Committee considers it appropriate, in its discretion. Any reasonable business-related expenses, in line with the Company’s expenses policy from time to time, may be reimbursed, including any taxes payable if reimbursement is determined to be a taxable benefit. Where necessary some or all expenses may be grossed up for taxes. | ||||
| Maximum | Reasonable market cost of providing the benefits. The Remuneration Committee shall have the discretion to introduce new benefits where these are introduced for the wider workforce, where it concludes that it is in the interests of the Company to do so, or which are considered necessary or desirable to support the executive in the execution of their duties, having regard to the particular circumstances of the individual. There is no overall defined maximum level of benefit. | ||||
| Performance conditions | N/A | ||||
| Pension | |||||
| Purpose and link to strategy | Enable the Executive Director to save for retirement and ensures their overall remuneration is competitive. | ||||
| Operation | The Executive Director is invited to participate in the pension arrangements in their local market and will receive the same level of contributions as other employees in that market. The Company may make payments of defined contribution pension contributions and pension allowances, which can either be made directly to the pension scheme or in cash via payroll. In the U.S., employees including the Executive Director may contribute into the Company's 401(k) Savings Plan, and the Company matches 100% up to the first 6% of employee contributions. A portion of the Executive Director’s contributions will be matched each pay period subject to annual IRS limits. The Company does not set aside or accrue any amounts to provide pension, retirement or similar benefits to executives. | ||||
| Maximum | The maximum percentage may not exceed the workforce rate. The Remuneration Committee has discretion to consider the relevant workforce rate including consideration of the relevant jurisdiction. | ||||
| Performance conditions | N/A | ||||
| Annual Bonus | |||||
| Purpose and link to strategy | The purpose of the Arm Annual Bonus Plan (as defined below) is to incentivize the Executive Director towards achieving stretching short-term goals based on the Company's strategy. | ||||
| Operation | The Remuneration Committee sets the performance conditions towards the beginning of each fiscal year with the relevant weightings, which are communicated to the Executive Director. The Remuneration Committee assesses performance at the end of the fiscal year against these targets. Any amount is fully paid in cash. The Remuneration Committee retains the right to exercise its discretion in the event that the formulaic outturn of the bonus does not reflect the Company or individual’s overall performance. | ||||
| Maximum | The maximum is 125% of salary for target performance. The plan may then pay up to 200% of target depending on performance plus any individual performance multiplier of up to 1.25x (312.5% of salary). | ||||
| Performance conditions | The performance conditions may include financial targets (including for example revenue and/or profit targets) and strategic measures, and/or any other measures that the Remuneration Committee considers appropriate, in its discretion. At least 50% of the performance conditions in any year will be financial targets. The exact measures, weightings, thresholds for vesting and targets are determined by the Remuneration Committee each year taking into account the Company's key strategic priorities and any other priorities which the Remuneration Committee considers are important, in its discretion, for the Executive Director to prioritize. No amounts are paid for below threshold performance. Maximum payment requires stretching levels of outperformance. | ||||
| Equity Awards | |||||
| Purpose and link to strategy | To incentivize the Executive Director towards achieving long-term goals based on the Company's strategy and to align their remuneration with shareholder interests. | ||||
| Operation | The Executive Director is granted equity awards annually which can take the form of RSUs, performance share units (“PSUs”), dividend equivalent rights, restricted shares, options or share appreciation rights (“SARs”) (or other forms of awards) under the Arm Holdings 2023 Omnibus Incentive Plan (the "Omnibus Incentive Plan") or successor plans. The Remuneration Committee will determine, in its discretion, the vesting and, if relevant, the performance conditions applicable to the awards of the Executive Director. Annual Awards to the Executive Director will vest over at least three years, subject to the Executive Director remaining in employment and subject to any performance conditions being met. Market price share options would have an overall life cycle of 10 years. Dividend equivalents may be paid on RSUs or PSUs to the extent that the awards vest. For the fiscal year ending March 31, 2025, awards will be made in the form of PSUs and it is anticipated that PSUs will form the majority or entirety of awards for the Executive Director in future years. The Remuneration Committee retains the right to exercise its discretion in the event that the formulaic outturn of the performance measures does not reflect the Company or individual’s overall performance. The Executive Director may also participate in any all employee share purchase plan or share option plan that is adopted by the Company on the same terms and conditions as other employees. | ||||
| Maximum | The maximum initial target value of the Annual Awards will be 14 times base salary (assessed at the time of grant). Awards may then vest up to 125% of the target value based on satisfaction of stretching performance conditions. | ||||
| Performance conditions | The performance conditions may include financial targets (including for example revenue and profit targets, or relative or absolute total shareholder return or earnings per share targets) and strategic measures. These will be set over a three year period and tested annually in relation to the relevant tranche and/or at the end of the three year performance period. The exact measures, weightings, thresholds for vesting and targets are determined by the Remuneration Committee, in its discretion, each year taking into account the Company's key strategic priorities. The targets will, where relevant, be determined in accordance with the Company's annual budget. No amounts are paid for below threshold performance. The Committee shall determine the extent to which the performance measures have been met and may make adjustments to the targets in the event that the Committee determines this is appropriate. Adjusted targets will be no less challenging as those originally set. | ||||
| Fees | |||||
| Purpose and link to strategy | To provide a fixed remuneration to the Non-Executive Director to reflect their responsibilities and to attract high caliber talent to the Board of Directors. The Non-Executive Chair’s fee (where paid) will typically be determined by the other members of the Remuneration Committee, and the Board of Directors is responsible for determining all other Non-Executive Director fees. | ||||
| Operation | Non-Executive Director fees consist of an annual cash retainer. In addition, each Non-Executive Director will receive a fee per meeting of the Board of Directors. Members of the Audit Committee and the Remuneration Committee, as well as the chairs of each committee, will receive a separate annual fee in cash. The Non-Executive Chair typically receives an annual cash retainer. However, Mr. Son has waived his eligibility and does not receive any remuneration from the Company. These fees will normally be paid quarterly. For the fiscal year ending March 31, 2025, Non-Executive Directors will receive an annual cash retainer of $80,000. In addition, each Non-Executive Director will receive a cash fee of $5,000 per meeting of the Board of Directors. Members of the Audit Committee and the Remuneration Committee will receive $15,000 and $10,000, respectively, in cash annually. The chairs of the Audit Committee and Remuneration Committee will receive $30,000 and $20,000, respectively in cash annually. As stated above, Mr. Son (the current Remuneration Committee Chair) does not receive any remuneration from the Company. Fees are reviewed on a regular basis and determined by reference to fee levels in the U.S. market, taking into account the expected time commitment and responsibilities involved. Non-Executive Directors will be reimbursed for expenses properly incurred in connection with the performance of their duties as a director, including, but not limited to, reasonable travel expenses. | ||||
| Maximum | Fees are set at an appropriate level taking into account the factors outlined in this table. Any Non-Executive Director who performs services which, in the opinion of the Board of Directors on recommendation from the Remuneration Committee, are outside the scope of the ordinary duties of a director, may be paid additional fees. | ||||
| Performance conditions | None. | ||||
| Equity Awards | |||||
| Purpose and link to strategy | To provide a fixed remuneration to the Non-Executive Directors to reflect their responsibilities and to attract high caliber talent to the Board of Directors while being linked to shareholder experience. | ||||
| Operation | Non-Executive Directors will receive an annual award of RSUs. The amount of the award is determined by the Board following recommendations from the Remuneration Committee. The Non-Executive Chair is typically eligible for an annual award. However, Mr. Son has waived his eligibility and does not receive any remuneration from the Company. The awards are not subject to performance conditions. The awards are subject to a 12-month vesting period. Non-Executive Directors are permitted to delay the vesting of their awards for up to 12 additional months. | ||||
| Maximum | The maximum is determined by the Board of Directors (on recommendation from the Remuneration Committee). The current value of RSUs awarded to each Non-Executive Director (other than Mr. Son) for the fiscal year ending March 31, 2025 is equivalent to $220,000. | ||||
| Performance conditions | None. | ||||
| Shareholding requirements | The Company has shareholding principles set out in its Corporate Governance Principles. The shareholding principles are summarized below. | ||||
| $000 | Salary | Taxable Benefits | Pension | Total Fixed Remune-ration | Annual Bonus | Special Bonus | Prior Plans | Total Variable Remune-ration | Total | |||||||||||||||||||||||
| Rene Haas | 2024 | $ | 1,350 | $ | 19 | $ | 14 | $ | 1,383 | $ | 2,468 | $ | 20,000 | $ | 46,282 | $ | 68,750 | $ | 70,133 | |||||||||||||
| Performance Condition | Measure | Weighting | Threshold (0%) | Target (100%) | Overall achievement | Outcome (% of overall max) | ||||||||||||||
| Financial: Target achievement (100% payment) | Revenue | 50% | $2,876 | $3,295 | $3,233 / 42.6% | 85% | ||||||||||||||
| Non-GAAP Operating Income | 50% | $1,268 | $1,459 | $1,408 / 36.6% | 73% | |||||||||||||||
| Strategic: Stretch (up to additional 50%) | Strategic business initiatives | 40% | Delivery of solutions and achievement of major design wins / key client adoption equally weighted across the four Lines of Business | 29.0% | 73% | |||||||||||||||
Organization | 10% | Delivery of operating model changes and increase in gender and racial/ethnic representation. | 8.8% | 88% | ||||||||||||||||
| Performance Condition | Measure | Weighting | Threshold (0%) | Target (100%) | Overall achievement | Outcome (% of overall max) | ||||||||||||||
| Financial: Target achievement (100% payment) | Revenue | 50% | $2,876 | $3,295 | $3,233 / 42.6% | 85% | ||||||||||||||
| Non-GAAP Operating Income | 50% | $1,268 | $1,459 | $1,408 / 36.6% | 73% | |||||||||||||||
| Strategic: Stretch (up to additional 100%) | Strategic business initiatives | 80% | Delivery of solutions and achievement of major design wins / key client adoption equally weighted across the four Lines of Business | 58.0% | 73% | |||||||||||||||
| Organization | 20% | Delivery of operating model changes and increase in gender and racial/ethnic representation. | 17.6% | 88% | ||||||||||||||||
$000 | Fees | Taxable Benefits | Total Fixed Remuneration | Prior Plans | Total Variable Remuneration | Total | |||||||||||||||||
| Masayoshi Son | 2024 | $— | $— | $— | $— | $— | $— | ||||||||||||||||
Karen E. Dykstra | 2024 | $135 | $— | $135 | $220 | $220 | $355 | ||||||||||||||||
Anthony Michael Fadell | 2024 | $85 | $— | $85 | $220 | $220 | $305 | ||||||||||||||||
Jeffrey A. Sine | 2024 | $115 | $— | $115 | $220 | $220 | $335 | ||||||||||||||||
Paul E. Jacobs, PhD | 2024 | $105 | $— | $105 | $220 | $220 | $325 | ||||||||||||||||
| Rosemary Schooler | 2024 | $121 | $— | $121 | $220 | $220 | $341 | ||||||||||||||||
Ronald D. Fisher | 2024 | $130 | $— | $130 | $220 | $220 | $350 | ||||||||||||||||
| Award type | Grant date | No. of shares under award | Face value ($000) | Threshold performance (% shares delivered) | End of performance period | |||||||||||||||
| Rene Haas | PSU | May 23, 2023 | 264,706 | $27,000 | —% | March 31, 2026 | ||||||||||||||
| Award type | Grant date | No. of shares under award | Face value ($000) | Threshold performance (% shares delivered) | End of performance period | |||||||||||||||
| Masayoshi Son | — | — | — | — | — | — | ||||||||||||||
Karen E. Dykstra | RSU | May 22, 2023 | 5,301 | $220 | 100% | May 15, 2024 | ||||||||||||||
Anthony Michael Fadell | RSU | May 22, 2023 | 5,301 | $220 | 100% | May 15, 2024 | ||||||||||||||
Jeffrey A. Sine | RSU | May 22, 2023 | 5,301 | $220 | 100% | May 15, 2024 | ||||||||||||||
Paul E. Jacobs, PhD | RSU | May 22, 2023 | 5,301 | $220 | 100% | May 15, 2024 | ||||||||||||||
| Rosemary Schooler | RSU | May 22, 2023 | 5,301 | $220 | 100% | May 15, 2024 | ||||||||||||||
Ronald D. Fisher | RSU | August 29, 2023 | 5,301 | $220 | 100% | May 15, 2024 | ||||||||||||||

| Year ended March 31, 2024 | |||||
CEO single figure ($000) | $70,133 | ||||
| Annual bonus as % of max | 59% | ||||
PSUs as % of max | 78% | ||||
| Fees ($) | |||||
| Non-Executive Director: Annual Cash Retainer | $80,000 | ||||
Board of Directors Meeting Attendance | $5,000 per meeting | ||||
| Audit Committee Chair | $30,000 | ||||
| Remuneration Committee Chair | $20,000 | ||||
| Audit Committee Members | $15,000 | ||||
| Remuneration Committee members | $10,000 | ||||
| Ownership of our outstanding ordinary shares: | Number of SoftBank Group candidates for election to our Board of Directors: | Number of SoftBank Group candidates that must be independent: | ||||||||||||
| Greater than 70% | 7 | 3 | ||||||||||||
| Less than or equal to 70% and greater than 60% | 6 | 2 | ||||||||||||
| Less than or equal to 60% and greater than 50% | 5 | 1 | ||||||||||||
| Less than or equal to 50% and greater than 40% | 4 | 0 | ||||||||||||
| Less than or equal to 40% and greater than 30% | 3 | 0 | ||||||||||||
| Less than or equal to 30% and greater than 20% | 2 | 0 | ||||||||||||
| Less than or equal to 20% and greater than 5% | 1 | 0 | ||||||||||||
| Function | March 31, 2024(1) | March 31, 2023 | March 31, 2022 | |||||||||||||||||
| Engineering | 5,887 | 4,753 | 4,758 | |||||||||||||||||
| Non-Engineering | 1,209 | 1,210 | 1,571 | |||||||||||||||||
| Geographic Distribution | ||||||||||||||||||||
| United Kingdom | 3,183 | 2,785 | 3,219 | |||||||||||||||||
| United States | 1,389 | 1,157 | 1,177 | |||||||||||||||||
| India | 1,150 | 848 | 793 | |||||||||||||||||
| Other | 1,374 | 1,173 | 1,140 | |||||||||||||||||
| Total Employees | 7,096 | 5,963 | 6,329 | |||||||||||||||||
| Ordinary Shares Beneficially Owned | |||||||||||||||||
| Name of Beneficial Shareholder | Number | Percent | |||||||||||||||
| 5% Shareholders: | |||||||||||||||||
SoftBank Group Corp.(1) | 922,733,999 | 88 | % | (2) | |||||||||||||
| Senior Management and Directors: | |||||||||||||||||
Masayoshi Son(1) | — | — | % | ||||||||||||||
| Ronald D. Fisher | * | * | |||||||||||||||
| Jeffrey A. Sine | * | * | |||||||||||||||
| Karen E. Dykstra | * | * | |||||||||||||||
| Anthony Michael Fadell | * | * | |||||||||||||||
| Rosemary Schooler | * | * | |||||||||||||||
| Paul E. Jacobs, PhD | * | * | |||||||||||||||
| Rene Haas | * | * | |||||||||||||||
| Jason Child | * | * | |||||||||||||||
| Kirsty Gill | * | * | |||||||||||||||
| Spencer Collins | * | * | |||||||||||||||
| Richard Grisenthwaite | * | * | |||||||||||||||
| Will Abbey | * | * | |||||||||||||||
| All Senior Management and Directors as a group (13 individuals) | * | * | |||||||||||||||
| Ownership of our outstanding ordinary shares: | Number of SoftBank Group candidates for election to our Board of Directors: | Number of SoftBank Group candidates that must be independent: | ||||||||||||
| Greater than 70% | 7 | 3 | ||||||||||||
| Less than or equal to 70% and greater than 60% | 6 | 2 | ||||||||||||
| Less than or equal to 60% and greater than 50% | 5 | 1 | ||||||||||||
| Less than or equal to 50% and greater than 40% | 4 | 0 | ||||||||||||
| Less than or equal to 40% and greater than 30% | 3 | 0 | ||||||||||||
| Less than or equal to 30% and greater than 20% | 2 | 0 | ||||||||||||
| Less than or equal to 20% and greater than 5% | 1 | 0 | ||||||||||||
| Page | |||||
Audited Consolidated Financial Statements | |||||
Report of Independent Registered Public Accounting Firm (Firm ID: | |||||
Consolidated Income Statements for the fiscal years ended March 31, 2024, 2023 and 2022 | |||||
Consolidated Statements of Comprehensive Income for the fiscal years ended March 31, 2024, 2023 and 2022 | |||||
Consolidated Balance Sheets as of March 31, 2024 and 2023 | |||||
Consolidated Statements of Shareholders’ Equity for the fiscal years ended March 31, 2024, 2023 and 2022 | |||||
Consolidated Statements of Cash Flows for the fiscal years ended March 31, 2024, 2023 and 2022 | |||||
| Fiscal Year Ended March 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Revenue: | |||||||||||||||||
| Revenue from external customers | $ | $ | $ | ||||||||||||||
| Revenue from related parties | |||||||||||||||||
| Total revenue | |||||||||||||||||
| Cost of sales | ( | ( | ( | ||||||||||||||
| Gross profit | |||||||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | ( | ( | ( | ||||||||||||||
| Selling, general and administrative | ( | ( | ( | ||||||||||||||
| Impairment of long-lived assets | ( | ||||||||||||||||
| Disposal, restructuring and other operating expenses, net | ( | ( | ( | ||||||||||||||
| Total operating expense | ( | ( | ( | ||||||||||||||
| Operating income (loss) | |||||||||||||||||
| Income (loss) from equity investments, net | ( | ( | |||||||||||||||
| Interest income, net | |||||||||||||||||
| Other non-operating income (loss), net | |||||||||||||||||
| Income (loss) before income taxes | |||||||||||||||||
| Income tax benefit (expense) | ( | ( | |||||||||||||||
| Net income (loss) from continuing operations | |||||||||||||||||
| Discontinued operations (Note 5): | |||||||||||||||||
| Loss from discontinued operations before income taxes | ( | ||||||||||||||||
| Income tax benefit (expense) from discontinued operations | ( | ||||||||||||||||
| Net loss from discontinued operations | ( | ||||||||||||||||
| Net income (loss) | $ | $ | $ | ||||||||||||||
| Net income (loss) per share attributable to ordinary shareholders – basic | |||||||||||||||||
| Net income from continuing operations | $ | $ | $ | ||||||||||||||
| Net loss from discontinued operations | $ | $ | $ | ( | |||||||||||||
| Net income (loss) per share - basic | $ | $ | $ | ||||||||||||||
| Net income (loss) per share attributable to ordinary shareholders – diluted | |||||||||||||||||
| Net income from continuing operations | $ | $ | $ | ||||||||||||||
| Net loss from discontinued operations | $ | $ | $ | ( | |||||||||||||
| Net income (loss) per share - diluted | $ | $ | $ | ||||||||||||||
| Weighted average ordinary shares outstanding | |||||||||||||||||
| Basic | |||||||||||||||||
| Diluted | |||||||||||||||||
| Fiscal Year Ended March 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Net income (loss) | $ | $ | $ | ||||||||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||
| Foreign currency translation adjustments | ( | ( | |||||||||||||||
| Net change of the effective portion of designated cash flow hedges | ( | ||||||||||||||||
| Total comprehensive income (loss) | $ | $ | $ | ||||||||||||||
| As of March 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Assets: | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Short-term investments | |||||||||||
Accounts receivable, net (including receivables from related parties of $ | |||||||||||
Contract assets (including contract assets from related parties of $ | |||||||||||
| Prepaid expenses and other current assets | |||||||||||
| Total current assets | |||||||||||
| Non-current assets: | |||||||||||
| Property and equipment, net | |||||||||||
| Operating lease right-of-use assets | |||||||||||
Equity investments (including investments held at fair value of $ | |||||||||||
| Goodwill | |||||||||||
| Intangible assets, net | |||||||||||
| Deferred tax assets | |||||||||||
| Non-current portion of contract assets | |||||||||||
| Other non-current assets | |||||||||||
| Total non-current assets | |||||||||||
| Total assets | $ | $ | |||||||||
| Liabilities: | |||||||||||
| Current liabilities: | |||||||||||
| Accrued compensation and benefits and share-based compensation | $ | $ | |||||||||
| Tax liabilities | |||||||||||
Contract liabilities (including contract liabilities from related parties of $ | |||||||||||
| Operating lease liabilities | |||||||||||
Other current liabilities (including payables to related parties of $ | |||||||||||
| Total current liabilities | |||||||||||
| Non-current liabilities: | |||||||||||
| Non-current portion of accrued compensation and share-based compensation | |||||||||||
| Deferred tax liabilities | |||||||||||
| Non-current portion of contract liabilities | |||||||||||
| Non-current portion of operating lease liabilities | |||||||||||
| Other non-current liabilities | |||||||||||
| Total non-current liabilities | |||||||||||
| Total liabilities | |||||||||||
| Commitments and contingencies (Note 19) | |||||||||||
| As of March 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Shareholders’ equity: | |||||||||||
Ordinary shares, $ | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated other comprehensive income | |||||||||||
| Retained earnings | |||||||||||
| Total shareholders’ equity | |||||||||||
| Total liabilities and shareholders’ equity | $ | $ | |||||||||
| Ordinary Shares | |||||||||||||||||||||||||||||||||||
| Number of Shares | Amount | Additional Paid- in Capital | Accumulated Other Comprehensive Income (Loss) | Retained Earnings | Total Shareholders’ Equity | ||||||||||||||||||||||||||||||
| Balance as of March 31, 2021 | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
| Net income (loss) | — | — | — | — | |||||||||||||||||||||||||||||||
| Foreign currency translation adjustments, net of tax | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||
| Distribution to ordinary shareholders related to Treasure Data and Arm China | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||
| Balance as of March 31, 2022 | |||||||||||||||||||||||||||||||||||
| Net income (loss) | — | — | — | — | |||||||||||||||||||||||||||||||
| Net change in fair value of the effective portion of designated cash flow hedges, net of tax | — | — | — | — | |||||||||||||||||||||||||||||||
| Foreign currency translation adjustments, net of tax | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||
| Share-based compensation cost | — | — | — | — | |||||||||||||||||||||||||||||||
| Balance as of March 31, 2023 | |||||||||||||||||||||||||||||||||||
| Net income (loss) | — | — | — | — | |||||||||||||||||||||||||||||||
| Net change in fair value of the effective portion of designated cash flow hedges, net of tax | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||
| Foreign currency translation adjustments, net of tax | — | — | — | — | |||||||||||||||||||||||||||||||
| Share-based compensation cost | — | — | — | — | |||||||||||||||||||||||||||||||
| Issuance of vested shares from share-based payment arrangements | — | — | — | — | — | ||||||||||||||||||||||||||||||
| Tax withholding on vested shares from share-based payment arrangements | ( | — | ( | — | — | ( | |||||||||||||||||||||||||||||
Reclassification of RSU awards previously liability-classified (1) | — | — | — | — | |||||||||||||||||||||||||||||||
| Distribution to majority ordinary shareholder related to Pelion IOT Limited | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||
| Balance as of March 31, 2024 | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||
| Fiscal Year Ended March 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Cash flows provided by (used for) operating activities: | |||||||||||||||||
Net income (loss) | $ | $ | $ | ||||||||||||||
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities: | |||||||||||||||||
Depreciation and amortization | |||||||||||||||||
Deferred income taxes | ( | ( | ( | ||||||||||||||
(Income) loss from equity investments, net | ( | ||||||||||||||||
Impairment losses on long-lived assets and loans receivable | |||||||||||||||||
Share-based compensation cost | |||||||||||||||||
Operating lease expense | |||||||||||||||||
Other non-cash operating activities, net | ( | ( | |||||||||||||||
Changes in assets and liabilities: | |||||||||||||||||
Accounts receivable, net (including receivables from related parties) | ( | ||||||||||||||||
Contract assets, net (including contract assets from related parties) | ( | ( | ( | ||||||||||||||
Prepaid expenses and other assets | ( | ( | ( | ||||||||||||||
Accrued compensation and benefits and share-based compensation | ( | ( | |||||||||||||||
Contract liabilities (including contract liabilities from related parties) | ( | ( | ( | ||||||||||||||
Tax liabilities | ( | ||||||||||||||||
Operating lease liabilities | ( | ( | ( | ||||||||||||||
Other liabilities (including payables to related parties) | |||||||||||||||||
Net cash provided by (used for) operating activities | $ | $ | $ | ||||||||||||||
Cash flows provided by (used for) investing activities | |||||||||||||||||
| Purchase of short-term investments | ( | ( | ( | ||||||||||||||
| Proceeds from maturity of short-term investments | |||||||||||||||||
Purchases of equity investments | ( | ( | ( | ||||||||||||||
Purchases of intangible assets | ( | ( | ( | ||||||||||||||
Purchases of property and equipment | ( | ( | ( | ||||||||||||||
Other investing activities, net, including investments in convertible loans | ( | ( | |||||||||||||||
Net cash provided by (used for) investing activities | $ | ( | $ | ( | $ | ( | |||||||||||
| Cash flows provided by (used for) financing activities | |||||||||||||||||
Cash transfers associated with distribution and sale of Treasure Data and IoTP, respectively | ( | ||||||||||||||||
| Payment of intangible asset obligations | ( | ( | ( | ||||||||||||||
Proceeds from short-term debt borrowing | |||||||||||||||||
Other financing activities, net | ( | ( | ( | ||||||||||||||
| Payment of withholding tax on vested shares | ( | ||||||||||||||||
Net cash provided by (used for) financing activities | $ | ( | $ | ( | $ | ( | |||||||||||
Effect of foreign exchange rate changes on cash and cash equivalents | ( | ( | |||||||||||||||
Net increase (decrease) in cash and cash equivalents | ( | ||||||||||||||||
Cash and cash equivalents at the beginning of the period | |||||||||||||||||
Cash and cash equivalents at the end of the period | $ | $ | $ | ||||||||||||||
| Fiscal Year Ended March 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Supplemental disclosure of cash flow information: | |||||||||||||||||
Cash payments for income taxes | $ | ( | $ | ( | $ | ( | |||||||||||
Cash refunds from income taxes | $ | $ | $ | ||||||||||||||
Cash payments for interest | $ | $ | $ | ( | |||||||||||||
| Non-cash operating, investing and financing activities: | |||||||||||||||||
Non-cash distributions associated with Arm China and Treasure Data | $ | $ | $ | ( | |||||||||||||
| Non-cash additions in property and equipment | $ | $ | $ | ||||||||||||||
| Non-cash additions in intangible assets | $ | $ | $ | ||||||||||||||
| Non-cash additions in operating lease right-of-use assets | $ | $ | $ | ||||||||||||||
| Non-cash additions of operating lease liabilities | $ | $ | $ | ||||||||||||||
| Non-cash additions to equity investments from conversion of certain receivables | $ | $ | $ | ||||||||||||||
| Non-cash distributions to shareholders | $ | $ | $ | ||||||||||||||
| Non-cash withholding tax on vested shares | $ | $ | $ | ||||||||||||||
| Non-cash reclassification of share-based compensation costs | $ | $ | $ | ||||||||||||||
| Patents and licenses | |||||
| Computer software | |||||
| Developed technology | |||||
| Customer relationships | |||||
| Trade names | |||||
| Buildings | |||||
| Leasehold improvements | Shorter of | ||||
| Equipment | |||||
| Fixtures and motor vehicles | |||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Accrued bonus, commissions, and cash awards | $ | $ | ||||||||||||
| Accrued vacation and sabbatical | ||||||||||||||
| Accrued salaries and fringe benefits | ||||||||||||||
Share-based payment liabilities (1) | ||||||||||||||
| Total accrued compensation and benefits and share-based compensation | $ | $ | ||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
Employee related payroll taxes and payables (1) | $ | $ | ||||||||||||
| Accrued expenses and fees | ||||||||||||||
| Electronic design automation liabilities | ||||||||||||||
Trade payables including payables to related parties of $ | ||||||||||||||
| Customer deposits | ||||||||||||||
| Total other current liabilities | $ | $ | ||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| External Customers | Related Parties | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | 2024 | 2023 | 2022 | 2024 | 2023 | 2022 | |||||||||||||||||||||||||||||||||||||||||||||||
License and Other Revenue (1) | $ | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Royalty Revenue | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| $ | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| United States | $ | $ | $ | |||||||||||||||||
PRC (1) | ||||||||||||||||||||
| Taiwan | ||||||||||||||||||||
| Republic of Korea | ||||||||||||||||||||
| Other countries | ||||||||||||||||||||
| Total | $ | $ | $ | |||||||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Trade receivables | $ | $ | ||||||||||||
| Royalty receivables | ||||||||||||||
| Total gross receivables | ||||||||||||||
| Allowance for current expected credit losses | ( | ( | ||||||||||||
| Total accounts receivables, net | $ | $ | ||||||||||||
| (in millions) | Total | |||||||
| Balance as of April 1, 2021 | $ | |||||||
| Additional provision | ||||||||
| Balance as of March 31, 2022 | $ | |||||||
| Reversal of provision | ( | |||||||
| Amounts written off during the year as uncollectible | ( | |||||||
| Balance as of March 31, 2023 | $ | |||||||
| Additional provision | ||||||||
Balance as of March 31, 2024 | $ | |||||||
| (in millions) | Total | |||||||
| Balance as of March 31, 2022 | $ | |||||||
| Customer prepayment and billing in advance of performance | ||||||||
| Revenue recognized in the period that was included in the contract liability balance at the beginning of the period | ( | |||||||
| Revenue recognized in the period that was included in the contract liability balance during the period | ( | |||||||
Effect of disposal (Note 21 - Related Party Transactions) | ( | |||||||
Balance as of March 31, 2023 | $ | |||||||
| Customer prepayment and billing in advance of performance | ||||||||
| Revenue recognized in the period that was included in the contract liability balance at the beginning of the period | ( | |||||||
| Revenue recognized in the period that was included in the contract liability balance during the period | ( | |||||||
Balance as of March 31, 2024 | $ | |||||||
| Fiscal Year Ended March 31, | ||||||||
| (in millions) | 2022 | |||||||
| Revenue from external customers | $ | |||||||
| Cost of sales | ( | |||||||
| Research and development | ( | |||||||
| Selling, general and administrative | ( | |||||||
| Restructuring and related costs | ||||||||
| Impairment of long-lived assets | ( | |||||||
| Loss from discontinued operations before income taxes | ( | |||||||
| Income tax (expense) benefit | ( | |||||||
| Net loss from discontinued operations | $ | ( | ||||||
| Fiscal Year Ended March 31, | ||||||||
| (in millions) | 2022 | |||||||
| Amortization and depreciation expense | $ | |||||||
| Other non-cash items | $ | |||||||
| As of March 31, | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Value | Weighted Average Remaining Life | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions except for years) | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||||||||||||||||||||||
| Patents & licenses | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||
| Developed technology | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Customer relationships | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||
| Computer software | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible assets subject to amortization | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible assets under development | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||
| Fiscal Years Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Cost of sales | $ | $ | $ | |||||||||||||||||
| Research and development | ||||||||||||||||||||
| Selling, general and administrative | ||||||||||||||||||||
| Total amortization expense | $ | $ | $ | |||||||||||||||||
| (in millions) | As of March 31, 2024 | |||||||
| 2025 | $ | |||||||
| 2026 | ||||||||
| 2027 | ||||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 and thereafter | ||||||||
| Total future amortization expense | $ | |||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Buildings | $ | $ | ||||||||||||
| Leasehold improvements | ||||||||||||||
| Equipment | ||||||||||||||
| Fixtures and motor vehicles | ||||||||||||||
| Construction in progress | ||||||||||||||
| Total property and equipment, gross | ||||||||||||||
| Less: Accumulated depreciation | ( | ( | ||||||||||||
| Total property and equipment, net | $ | $ | ||||||||||||
| As of March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Cash flows used for operating leases | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Operating lease right-of-use assets obtained in exchange for lease obligations | $ | $ | $ | |||||||||||||||||
| As of March 31, | |||||||||||||||||
| 2024 | 2023 | 2022 | |||||||||||||||
| Weighted average discount rate | % | % | % | ||||||||||||||
| Weighted average remaining lease term (in years) | |||||||||||||||||
| Fiscal Year | Total | |||||||
| 2025 | $ | |||||||
| 2026 | ||||||||
| 2027 | ||||||||
| 2028 | ||||||||
| 2029 | ||||||||
| Thereafter | ||||||||
| Total minimum lease payments | ||||||||
| Less imputed interest | ( | |||||||
| Total operating lease liabilities | ||||||||
| Less: current portion of operating lease liabilities | ||||||||
| Non-current portion of operating lease liabilities | $ | |||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Equity method investments under fair value option | $ | $ | ||||||||||||
| Equity method investments under equity method | ||||||||||||||
| Non-marketable equity securities | ||||||||||||||
| Total equity investments | $ | $ | ||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
Equity method investments (1) | $ | ( | $ | ( | $ | |||||||||||||||
| Non-marketable equity securities (includes NAV) | ( | ( | ||||||||||||||||||
| Total loss from equity investments, net | $ | ( | $ | ( | $ | |||||||||||||||
| Name | Ownership Interest % | |||||||
| Arm IOT Fund LP (Taiwan) | ||||||||
| Accelerator Advisory Limited | ||||||||
| HOPU-ARM Holding Company Limited | ||||||||
| DeepTech Labs Fund 1 LP | ||||||||
| Name | Ownership Interest % | |||||||
| Acetone Limited | ||||||||
| Ampere Computing Holdings LLC (“Ampere”) | ||||||||
| China Walden Ventures Investments II, L.P. —NAV | ||||||||
| China Walden Ventures Investments III, L.P. —NAV | ||||||||
| HOPU-ARM Innovation Fund, L.P. —NAV | ||||||||
| Catapult Ventures I, L.P. —NAV | ||||||||
| Fiscal Year Ended March 31, | |||||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | ||||||||||||||||||||
| Observable price adjustments on non-marketable equity securities (includes NAV) | $ | $ | $ | ||||||||||||||||||||
| Impairment of non-marketable equity securities | ( | ( | ( | ||||||||||||||||||||
| Sale of non-marketable equity securities | |||||||||||||||||||||||
| Total income (loss) from equity investments in non-marketable securities, net | $ | ( | $ | ( | $ | ||||||||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Loans and other receivables carried at amortized cost | ||||||||||||||
| Loans receivable | $ | $ | ||||||||||||
| Other receivables | ||||||||||||||
| Allowance for current expected credit losses | ( | ( | ||||||||||||
| Loans and other receivables carried at amortized cost, net | $ | $ | ||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Designated as cash flow hedges | ||||||||||||||
| Foreign currency forward contracts | $ | $ | ||||||||||||
| Derivative Assets | Derivative Liabilities | |||||||||||||||||||||||||
| As of March 31, | As of March 31, | |||||||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||||
| Designated as cash flow hedges | ||||||||||||||||||||||||||
| Foreign currency forward contracts | $ | $ | $ | $ | ||||||||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Consolidated Statements of Comprehensive Income: | ||||||||||||||||||||
| Gains (losses) reclassified in Accumulated other comprehensive income on cash flow hedge derivatives | $ | $ | $ | |||||||||||||||||
| (Gains) losses reclassified from Accumulated other comprehensive income into income | ( | |||||||||||||||||||
| Income tax benefit (expense) on cash flow hedges | ( | |||||||||||||||||||
Net change in fair value of the effective portion of designated cash flow hedges, net of tax (1) | $ | ( | $ | $ | ||||||||||||||||
| Consolidated Income Statements, before tax: | ||||||||||||||||||||
| Research and development | $ | $ | ( | $ | ||||||||||||||||
| Selling, general and administrative expenses | $ | $ | ( | $ | ||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Foreign currency forward contracts | $ | ( | $ | ( | $ | ( | ||||||||||||||
| As of March 31, 2024 | As of March 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||||||||||||||||||
| Financial liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency forward contracts | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| Total financial liabilities | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| As of March 31, 2024 | As of March 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||||||||||||||||||||||||
| Financial assets | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Money market funds | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
Short-term investments(1) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Equity method investments(2) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Convertible loans receivable | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency forward contracts | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Total financial assets | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Fair value of financial assets at the beginning of the period | $ | $ | ||||||||||||
| Additions, net of contributions from shareholders of the Company | ||||||||||||||
| Fair value losses recognized in the Consolidated Income Statements | ( | ( | ||||||||||||
| Distributions to shareholders of the Company | ||||||||||||||
| Fair value at the end of the period | $ | $ | ||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Fair value of financial assets at the beginning of the period | $ | $ | ||||||||||||
| Additions | ||||||||||||||
| Converted into equity | ||||||||||||||
| Fair value gains recognized in the income statement | ||||||||||||||
| Fair value at the end of the period | $ | $ | ||||||||||||
As of March 31, 2024 | ||||||||||||||||||||||||||
| (in millions) | Fair value | Valuation Technique | Unobservable Inputs | Range of Estimates | ||||||||||||||||||||||
| Equity Method Investments | $ | Acetone – Market-Calibration or discounted cash flow | LTM Revenue Multiple | |||||||||||||||||||||||
| Ampere – PWER | Probability of initial public offering, time to future exit scenario, discount rate | Probability weighted – | ||||||||||||||||||||||||
As of March 31, 2023 | ||||||||||||||||||||||||||
| (in millions) | Fair value | Valuation Technique | Unobservable Inputs | Range of Estimates | ||||||||||||||||||||||
| Equity Method Investments | $ | Acetone – Market-Calibration or discounted cash flow | LTM Revenue Multiple | |||||||||||||||||||||||
| Ampere – PWER | Probability of initial public offering, time to future exit scenario, discount rate | Probability weighted – | ||||||||||||||||||||||||
| Awards | Weighted Average Fair Value Per Award (1) | |||||||||||||
| Outstanding as of March 31, 2023 | $ | |||||||||||||
| Granted | $ | |||||||||||||
| Vested | ( | $ | ||||||||||||
| Cancelled and forfeited | ( | $ | ||||||||||||
| Outstanding and expected to vest as of March 31, 2024 | $ | |||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| 2024 | 2023 | 2022 | ||||||||||||||||||
| Weighted average share price | $ | $ | $ | |||||||||||||||||
| Expected volatility until liquidity event | % | % | % | |||||||||||||||||
| Time to liquidity event | ||||||||||||||||||||
| Dividend yield | % | % | % | |||||||||||||||||
| Risk free interest rate | % | % | % | |||||||||||||||||
| Awards | Weighted Average Fair Value Per Award (1) | |||||||||||||
| Outstanding as of March 31, 2023 | $ | |||||||||||||
| Vested | ( | $ | ||||||||||||
| Outstanding and expected to vest as of March 31, 2024 | $ | |||||||||||||
Weighted average share price | $ | |||||||
Expected volatility until liquidity event | ||||||||
Time to liquidity event | ||||||||
Dividend yield | ||||||||
Risk free interest rate | ||||||||
| Average share price | $ | |||||||
| Transaction costs | % | |||||||
| Time to liquidity event (in years) | ||||||||
| Discount for lack of marketability | % | |||||||
| Fiscal year ended | ||||||||||||||
| March 31, 2023 | ||||||||||||||
| Type of Executive Award (in millions) | Potential Fixed Monetary Amount | Accrued Liability (1) | ||||||||||||
| Launch Awards | $ | $ | ||||||||||||
| Annual Awards | ||||||||||||||
| Total | $ | $ | ||||||||||||
Awards(1) | Weighted Average Grant Date Fair Value Per Award(1) | |||||||||||||
| Outstanding as of March 31, 2023 | $ | |||||||||||||
Executive Awards converted from liability awards | $ | |||||||||||||
| Granted | $ | |||||||||||||
Vested (2) | ( | $ | ||||||||||||
| Cancelled and forfeited | ( | $ | ||||||||||||
| Outstanding and expected to vest as of March 31, 2024 | $ | |||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Average share price | $ | $ | ||||||||||||
| Transaction costs | % | % | ||||||||||||
| Present value per RSU | $ | $ | ||||||||||||
| Time to liquidity event (in years) | ||||||||||||||
| Discount for lack of marketability | ||||||||||||||
Awards(1) | Weighted Average Grant Date Fair Value Per Award(1) | |||||||||||||
Outstanding as of March 31, 2023 | $ | |||||||||||||
| Granted | $ | |||||||||||||
| Vested | ( | $ | ||||||||||||
| Cancelled and forfeited | ( | $ | ||||||||||||
Outstanding and expected to vest as of March 31, 2024 | $ | |||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2022 | 2022 | |||||||||||||||||
Cost of sales | $ | $ | $ | |||||||||||||||||
Research and development | ||||||||||||||||||||
Selling, general and administrative | ||||||||||||||||||||
Total | $ | $ | $ | |||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| United Kingdom | $ | $ | $ | |||||||||||||||||
| Foreign | ||||||||||||||||||||
| Income from continuing operations before income taxes | $ | $ | $ | |||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Current: | ||||||||||||||||||||
| United Kingdom | $ | $ | ( | $ | ( | |||||||||||||||
| Foreign | ( | ( | ( | |||||||||||||||||
| Total current tax (expense) benefit | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Deferred: | ||||||||||||||||||||
| United Kingdom | $ | $ | $ | ( | ||||||||||||||||
| Foreign | ||||||||||||||||||||
| Total deferred tax (expense) benefit | $ | $ | $ | |||||||||||||||||
| Total income tax (expense) benefit | $ | $ | ( | $ | ( | |||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Income tax (expense) benefit at statutory rate | $ | ( | $ | ( | $ | ( | ||||||||||||||
| Foreign tax rate differential | ( | ( | ||||||||||||||||||
| Research and development tax credits | ||||||||||||||||||||
| Change in valuation allowance | ( | ( | ||||||||||||||||||
| Non-deductible/non-taxable items | ( | ( | ||||||||||||||||||
| Patent box benefit | ( | |||||||||||||||||||
| Impact of U.K. rate change | ( | ( | ( | |||||||||||||||||
| Withholding tax | ( | ( | ( | |||||||||||||||||
| Gains exempt from U.K. tax | ( | |||||||||||||||||||
| Windfall tax benefit associated with share-based compensation | ||||||||||||||||||||
| Income tax (expense) benefit | $ | $ | ( | $ | ( | |||||||||||||||
| Income tax (expense) benefit reported in the Consolidated Income Statements | ( | ( | ||||||||||||||||||
| Income tax (expense) benefit attributable to discontinued operations | ( | |||||||||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| Lease liability | $ | $ | ||||||||||||
| Fixed assets | ||||||||||||||
| Tax losses and R&D tax credits | ||||||||||||||
| Equity investments | ||||||||||||||
| Share-based compensation | ||||||||||||||
| Reserves and other liabilities | ||||||||||||||
| Total gross deferred tax assets | ||||||||||||||
| Less: Valuation allowance | ( | ( | ||||||||||||
| Total deferred tax assets, net of valuation allowance | ||||||||||||||
| Right of use assets | ( | ( | ||||||||||||
| Acquired intangibles | ( | ( | ||||||||||||
| Outside basis differences | ( | ( | ||||||||||||
| Hedging reserve | ( | |||||||||||||
| Contract liabilities | ( | ( | ||||||||||||
| Total deferred tax liabilities | ( | ( | ||||||||||||
| Net deferred tax assets (liabilities) | $ | $ | ( | |||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| (in millions) | 2024 | 2023 | 2022 | |||||||||||||||||
| Gross unrecognized tax benefits—April 1 | $ | $ | $ | |||||||||||||||||
| Gross increases—tax positions in prior period | ||||||||||||||||||||
| Gross decreases—tax positions in prior period | ( | |||||||||||||||||||
| Gross increases—tax positions in current period | ||||||||||||||||||||
| Settlements | ( | ( | ||||||||||||||||||
| Lapse of statute of limitations | ( | ( | ||||||||||||||||||
| Foreign exchange | ( | ( | ( | |||||||||||||||||
| Gross unrecognized tax benefits— March 31 | $ | $ | $ | |||||||||||||||||
| Fiscal Years Ended March 31, | ||||||||||||||||||||
(in millions, except shares and per share amounts) | 2024 | 2023 | 2022 | |||||||||||||||||
Income (loss) attributable to ordinary shareholders — basic and diluted | ||||||||||||||||||||
Net income from continuing operations | $ | $ | $ | |||||||||||||||||
Net loss from discontinued operations | ( | |||||||||||||||||||
Net income (loss) | $ | $ | $ | |||||||||||||||||
Weighted average ordinary shares used to calculate income (loss) per share — basic (1) | ||||||||||||||||||||
Equity-classified shared-based awards | ||||||||||||||||||||
Weighted average ordinary shares used to calculate income (loss) per share — diluted | ||||||||||||||||||||
Income (loss) per share attributable to ordinary shareholders — basic | ||||||||||||||||||||
Net income from continuing operations | $ | $ | $ | |||||||||||||||||
Net loss from discontinued operations | ( | |||||||||||||||||||
Net income (loss) per share - basic | $ | $ | $ | |||||||||||||||||
Income (loss) per share attributable to ordinary shareholders — diluted | ||||||||||||||||||||
Net income from continuing operations | $ | $ | $ | |||||||||||||||||
Net loss from discontinued operations | ( | |||||||||||||||||||
Net income (loss) per share - diluted | $ | $ | $ | |||||||||||||||||
| Fiscal Year Ended March 31, | ||||||||||||||||||||
| 2024 | 2023 | 2022 | ||||||||||||||||||
Restricted stock units (1) | ||||||||||||||||||||
Executive awards (2) | ||||||||||||||||||||
| Total | ||||||||||||||||||||
| As of March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
| United Kingdom | $ | $ | ||||||||||||
| United States | ||||||||||||||
| Other countries | ||||||||||||||
| Total | $ | $ | ||||||||||||
| Service | Fee | |||||||
| Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares or upon a change in the ADS(s)-to-ordinary shares ratio or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) issued. | |||||||
| Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property or upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason) | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled. | |||||||
| Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements) | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held. | |||||||
| Distribution of ADSs pursuant to (i) share dividends or other free share distributions, or (ii) an exercise of rights to purchase additional ADSs | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held. | |||||||
| Distribution of financial instruments, including, without limitation, securities, other than ADSs or rights to purchase additional ADSs (e.g., spin-off shares and contingent value rights) | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held. | |||||||
| ADS Services | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the depositary. | |||||||
| Registration of ADS Transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and vice versa, or for any other reason) | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) transferred. | |||||||
| Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the deposit agreement) into freely transferable ADSs, and vice versa) or conversion of ADSs for unsponsored American Depositary Shares (e.g., upon termination of the deposit agreement) | Up to U.S. $5.00 per 100 ADSs (or fraction thereof) converted. | |||||||
| Fiscal Year Ended March 31, | ||||||||||||||
| (in millions) | 2024 | 2023 | ||||||||||||
Audit fees (1) | $ | 11 | $ | 12 | ||||||||||
Audit-related fees (2) | — | 1 | ||||||||||||
Tax fees (3) | — | — | ||||||||||||
| All other fees | 1 | — | ||||||||||||
| Total | $ | 12 | $ | 13 | ||||||||||
| Issuer Purchases of Equity Securities | ||||||||||||||
| Period | (a) Total number of shares purchased (1) | (b) Average price paid per share (1) | (c) Total number of shares purchased as part of publicly announced plans or programs | (d) Maximum number of shares that may yet be purchased under the plans or programs | ||||||||||
| April 1, 2023 to April 30, 2023 | — | $ | — | — | — | |||||||||
| May 1, 2023 to May 31, 2023 | — | $ | — | — | — | |||||||||
| June 1, 2023 to June 30, 2023 | — | $ | — | — | — | |||||||||
| July 1, 2023 to July 31, 2023 | — | $ | — | — | — | |||||||||
| August 1, 2023 to August 31, 2023 | — | $ | — | — | — | |||||||||
| September 1, 2023 to September 30, 2023 | — | $ | — | — | — | |||||||||
| October 1, 2023 to October 31, 2023 | 388,530 | $ | 53.45 | — | — | |||||||||
| November 1, 2023 to November 30, 2023 | 1,581,222 | $ | 55.43 | — | — | |||||||||
| December 1, 2023 to December 31, 2023 | — | $ | — | — | — | |||||||||
| January 1, 2024 to January 31, 2024 | — | $ | — | — | — | |||||||||
| February 1, 2024 to February 29, 2024 | 724,954 | $ | 131.54 | — | — | |||||||||
| March 1, 2024 to March 31, 2024 | 70,713 | $ | 139.47 | — | — | |||||||||
| Total | 2,765,419 | $ | 77.25 | — | — | |||||||||
| Exhibit Number | Description of Exhibit | Form | File No. | Exhibit | Filing Date | Filed Herewith | ||||||||||||||||||||||||||||||||
| 1.1 | X | |||||||||||||||||||||||||||||||||||||
| 2.1 | X | |||||||||||||||||||||||||||||||||||||
| 2.2 | Form of American Depositary Receipt (included in exhibit 2.1). | X | ||||||||||||||||||||||||||||||||||||
| 2.3 | X | |||||||||||||||||||||||||||||||||||||
| 4.1 | Arm IP License Agreement, dated April 24, 2018, by and between Arm Limited and Arm Technology (China) Co. Ltd. | F-1 | 333-274120 | 10.1 | 08/21/2023 | |||||||||||||||||||||||||||||||||
| 4.2 | X | |||||||||||||||||||||||||||||||||||||
| 4.3 | X | |||||||||||||||||||||||||||||||||||||
| 4.4 | Consulting Agreement, dated August 21, 2023, by and between Arm Limited and SoftBank Group Corp. | F-1 | 333-274120 | 10.4 | 09/01/2023 | |||||||||||||||||||||||||||||||||
| 4.5 | Form of Deed of Indemnity between the Company and each of its directors. | F-1 | 333-274120 | 10.5 | 09/05/2023 | |||||||||||||||||||||||||||||||||
| 4.6 | Form of Deed of Indemnity between the Company and each of its executive officers. | F-1 | 333-274120 | 10.6 | 09/05/2023 | |||||||||||||||||||||||||||||||||
| 4.7 | The Arm Holdings plc RSU Award Plan with California and Israeli Sub-Plans. | S-8 | 333-274544 | 4.6 | 09/15/2023 | |||||||||||||||||||||||||||||||||
| 4.8 | The Arm Holdings plc All-Employee Plan 2019 with California and French Sub-Plans. | S-8 | 333-274544 | 4.7 | 09/15/2023 | |||||||||||||||||||||||||||||||||
| 4.9 | The Executive IPO Plan 2019 with California Sub-Plan. | S-8 | 333-274544 | 4.8 | 09/15/2023 | |||||||||||||||||||||||||||||||||
| 4.10 | The Arm Non-Executive Directors RSU Award Plan with California Sub-Plan. | S-8 | 333-274544 | 4.9 | 09/15/2023 | |||||||||||||||||||||||||||||||||
| 4.11 | X | |||||||||||||||||||||||||||||||||||||
| 4.12 | X | |||||||||||||||||||||||||||||||||||||
| 8.1 | X | |||||||||||||||||||||||||||||||||||||
| 11.1 | X | |||||||||||||||||||||||||||||||||||||
| 12.1 | X | |||||||||||||||||||||||||||||||||||||
| 12.2 | X | |||||||||||||||||||||||||||||||||||||
| 13.1 | * | |||||||||||||||||||||||||||||||||||||
| 15.1 | X | |||||||||||||||||||||||||||||||||||||
| 97.1 | X | |||||||||||||||||||||||||||||||||||||
| 101 | The following materials from the Company’s Annual Report on Form 20-F for the year ended March 31, 2024, were formatted in Inline XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Statements of Shareholders’ Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | ||||||||||||||||||||||||||||||||||||
| 104 | Cover page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL. | X | ||||||||||||||||||||||||||||||||||||
ARM HOLDINGS PLC | ||||||||
Date: May 29, 2024 | By: | /s/ Laura Bartels | ||||||
Name: | Laura Bartels | |||||||
Title: | Chief Accounting Officer (Principal Accounting Officer) | |||||||